Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew M Hutmacher

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|January 25, 2007
Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasisMatthew M Hutmacher, Ivan Nestorov, Tom Ludden, et al.
Journal of Clinical Pharmacology|June 16, 2015
Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic painMatthew M Hutmacher, Bill Frame, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 2, 2005
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonistMatthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
The AAPS Journal|January 29, 2013
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolitesMark Stroh, Matthew M Hutmacher, Jianmei Pang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 25, 2012
Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary diseaseJace C Nielsen, Matthew M Hutmacher, Adriaan Cleton, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patientsNeeraj Gupta, Yeamin Huh, Matthew M Hutmacher, et al.
Journal of Clinical Pharmacology|January 18, 2008
Performance characteristics for some typical QT study designs under the ICH E-14 guidanceMatthew M Hutmacher, Sunny Chapel, Marilyn A Agin, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 4, 2015
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edemaAnthony S Basile, Matthew M Hutmacher, Kenneth G Kowalski, et al.
Journal of Clinical Pharmacology|August 14, 2014
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizuresJace C Nielsen, Matthew M Hutmacher, David L Wesche, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|January 25, 2007
Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasisMatthew M Hutmacher, Ivan Nestorov, Tom Ludden, et al.
Journal of Clinical Pharmacology|June 16, 2015
Exposure-response modeling of average daily pain score, and dizziness and somnolence, for mirogabalin (DS-5565) in patients with diabetic peripheral neuropathic painMatthew M Hutmacher, Bill Frame, Raymond Miller, et al.
Journal of Pharmacokinetics and Pharmacodynamics|December 2, 2005
Collapsing mechanistic models: an application to dose selection for proof of concept of a selective irreversible antagonistMatthew M Hutmacher, Debu Mukherjee, Kenneth G Kowalski, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 24, 2004
A two-part mixture model for longitudinal adverse event severity dataKenneth G Kowalski, Lynn McFadyen, Matthew M Hutmacher, et al.
The AAPS Journal|January 29, 2013
Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolitesMark Stroh, Matthew M Hutmacher, Jianmei Pang, et al.
Journal of Pharmacokinetics and Pharmacodynamics|September 25, 2012
Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary diseaseJace C Nielsen, Matthew M Hutmacher, Adriaan Cleton, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2015
Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patientsNeeraj Gupta, Yeamin Huh, Matthew M Hutmacher, et al.
Journal of Clinical Pharmacology|January 18, 2008
Performance characteristics for some typical QT study designs under the ICH E-14 guidanceMatthew M Hutmacher, Sunny Chapel, Marilyn A Agin, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 4, 2015
Population pharmacokinetics of pegaptanib sodium (Macugen(®)) in patients with diabetic macular edemaAnthony S Basile, Matthew M Hutmacher, Kenneth G Kowalski, et al.
Journal of Clinical Pharmacology|August 14, 2014
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizuresJace C Nielsen, Matthew M Hutmacher, David L Wesche, et al.
Pageof 3